Xuchen Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xuchen Cao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Huilai Zhang
Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2 shared publications Lanfang Li
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin 300060, China
2 shared publicationsLihua Qiu
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin 300060, China
2 shared publicationsPeiqi Zhao
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin 300060, China
2 shared publicationsShiyong Zhou
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin 300060, China
2 shared publicationsXianming Liu
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin 300060, China
2 shared publications
Latest Publications
- 1 March 2018
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 84, 108-117
TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance
- 1 March 2018
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 84, 108-117
TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance
- 1 October 2017
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 79, 191-198
Upconverting and persistent luminescent nanocarriers for accurately imaging-guided photothermal therapy
- 1 October 2017
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 79, 191-198
Upconverting and persistent luminescent nanocarriers for accurately imaging-guided photothermal therapy
- 1 August 2015
- Vol. 8 (8) , 9500-5
Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer.
To explore the methylation status of DNA-binding inhibitor 4 (ID4) in tamoxifen-refractory (TR) breast cancer. From January 2012 to December 2014, breast cancer patients managed by radical mastectomy previously and receiving tamoxifen treatment for at least 12 months were enrolled. According to the response to tamoxifen, patients were divided into TR group and tamoxifen-sensitive (TS) group. Genomic DNA was isolated from fasting venous blood, and methylight technique was applied to determine the methylation status of ID4. 43 patients with TS breast cancer and 31 patients with TR breast cancer were enrolled. No significant difference between groups was observed in term of patients' characteristics, such as age (P=0.693), progesterone receptor (P=0.970), menopausal status (P=0.784) and histological type (P=0.537), while the stage of cancer in TR group was significantly higher than TS group (P<0.001). Compared to TS group, PMR of ID4 was significantly higher in TR group (P=0.002). ROC curve analysis indicated that ID4 yielded an AUC of 0.716 with 77.4% sensitivity and 62.79% specificity in distinguishing TR breast cancer at the cut point of 3.8%. The PMR cut point of ID4 was set at 6.8% in survival analysis, log-rank test indicated the risk of disease progression was comparable between patients with ID4 hypermethylation or hypomethylation (P=0.287). ID4 hypomethylation is present in TR breast cancer, and it may serve as a potential biomarker in distinguishing TR breast cancer. However, the results need further validation in larger studies.
- 1 August 2015
- Vol. 8 (8) , 9500-5
Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer.
To explore the methylation status of DNA-binding inhibitor 4 (ID4) in tamoxifen-refractory (TR) breast cancer. From January 2012 to December 2014, breast cancer patients managed by radical mastectomy previously and receiving tamoxifen treatment for at least 12 months were enrolled. According to the response to tamoxifen, patients were divided into TR group and tamoxifen-sensitive (TS) group. Genomic DNA was isolated from fasting venous blood, and methylight technique was applied to determine the methylation status of ID4. 43 patients with TS breast cancer and 31 patients with TR breast cancer were enrolled. No significant difference between groups was observed in term of patients' characteristics, such as age (P=0.693), progesterone receptor (P=0.970), menopausal status (P=0.784) and histological type (P=0.537), while the stage of cancer in TR group was significantly higher than TS group (P<0.001). Compared to TS group, PMR of ID4 was significantly higher in TR group (P=0.002). ROC curve analysis indicated that ID4 yielded an AUC of 0.716 with 77.4% sensitivity and 62.79% specificity in distinguishing TR breast cancer at the cut point of 3.8%. The PMR cut point of ID4 was set at 6.8% in survival analysis, log-rank test indicated the risk of disease progression was comparable between patients with ID4 hypermethylation or hypomethylation (P=0.287). ID4 hypomethylation is present in TR breast cancer, and it may serve as a potential biomarker in distinguishing TR breast cancer. However, the results need further validation in larger studies.